Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

@article{Warlick2012ReducedIC,
  title={Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.},
  author={Erica D. Warlick and Kwang Woo Ahn and Tanya L. Pedersen and Andrew S. Artz and Marcos de Lima and Michael A. Pulsipher and Gorgun Akpek and Mahmoud Aljurf and Jean Yves Cahn and Mitchell S. Cairo and Yi-Bin Chen and Brenda W. Cooper and Abhinav Deol and Sergio A. Giralt and Vikas Gupta and H. Jean Khoury and Holbrook E. Kohrt and Hillard M. Lazarus and Ian D. Lewis and Richard F. Olsson and Joseph Pidala and Bipin N. Savani and Matthew D. Seftel and G{\'e}rard Soci{\'e} and Martin S. Tallman and Celaettin Ustun and Ravi Vij and Lars Vindel{\o}v and Daniel J. Weisdorf},
  journal={Blood},
  year={2012},
  volume={119 17},
  pages={
          4083-90
        }
}
Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Establishing a Hematopoietic Stem Cell Transplantation Unit

  • Springer International Publishing
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Alloge - neic stem cell transplantation for patients harboring T 315 I BCR - ABL mutated leukemias

FE Nicolini, GW Basak, S Soverini
  • 2010